We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Manal Abdelmalek

Manal F. Abdelmalek MD, MPH

Professor of Medicine, Division of Gastroenterology & Hepaotology, Duke University, Durham, North Carolina

Manal F. Abdelmalek, MD, MPH, is tenured Professor of Medicine in the Division of Gastroenterology and Hepatology at Duke University and Director of the NAFLD Clinical Research Program at Duke University. She received training in Internal Medicine, Gastroenterology and Hepatology at the Mayo Clinic, Scottsdale AZ and Rochester, MN. She obtained a MPH degree with emphasis in epidemiology, public health and clinical investigation at the University of Florida, Gainesville, Florida. Her clinical and research area of interest is in the field of nonalcoholic fatty liver disease (NAFLD) since first reporting NASH as a cause of cryptogenic cirrhosis over 20 years ago. She has expertise in the design and conduct of clinical trials in NAFLD/ NASH including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD. She collaborates extensively to transition new compounds to first-in-man clinical studies and the translation of clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She is a standing member of NASH Clinical Research Network (NASH CRN). She has over 150 publications authored publications in the field of liver disease, the majority of which are in the area of NAFLD.

Disclosures

Dr. Abdelmalek discloses the following:

Research/Grants: Conatus, Gilead, Genfit, Galactin, Intercept, Allergan, Madrigal, Novo-Nordisk, POXEL, Durect, Enyo, Enanta, Metabolon, Progenity, Boeringher-Ingelheim, Bristol Myers Squibb, NGM Bio, Viking, Prometheus, Immuron, TaiwanJ, NIH/ NIDDK

Consulting/Advisory Board: Allergan, NGM Bio, Madrigal, Bristol Myers Squibb, TaiwanJ, Novo-Nordisk, ProSciento, Prometic

Speakers Bureaus: iHEP NASH, Clinical Care Options, NASH Education, MedScape Education, Intercept. Alexion